Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

SAFFRON Data Reveal New Global SOC in EGFR+ NSCLC With MET Overexpression and ...

25 October 2026 · By · Wire by Fusion42

Published

25 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Global

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 25 October 2026 · Fusion42 review

The phase 3 SAFFRON trial showed that osimertinib plus savolitinib significantly improved progression-free and overall survival compared to platinum/pemetrexed chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression or amplification after progression on osimertinib.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can enter the post-osimertinib NSCLC market with a therapy that now sets a new survival standard, shifting patient options beyond chemotherapy. The approval of this combo places savolitinib and osimertinib as key competitors to traditional chemo providers in MET-driven lung cancer.

◆ Coverage

1 source · 25 Oct 2026

◆ Related on Wire

◆ Topics

Biotechnsclcegfrmet-overexpressionosimertinibsavolitinibclinical-trial